SciELO - Scientific Electronic Library Online

 
vol.18 número2Gestão baseada em evidencias na área de cirurgia no Hospital General de Playa del Carmen, 2015 - 2016 índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Horizonte sanitario

versão On-line ISSN 2007-7459versão impressa ISSN 1665-3262

Resumo

CRUZ BARRIOS, María Aida  e  FURONES MOURELLE, Juan Antonio. Benefit-risk use of transfer factor (Hebertrans®) in usual medical practice. Horiz. sanitario [online]. 2019, vol.18, n.2, pp.235-242. ISSN 2007-7459.  https://doi.org/10.19136/hs.a18n2.2918.

Objectives.

Analyze the benefit-risk ratio of FT (Hebertrans®) in medical practice.

Method:

The Bayesian approach was used to compare the likelihood of benefit (satisfactory evolution of patients) with risk (presence of adverse reactions during or after treatment). The information was obtained from publications investigating adverse reactions and the clinical evolution of patients treated with Hebertrans®.

Results:

A higher percentage of adverse reactions was observed with patients who evolved in an unsatisfactory way (24.5%), than among those who progressed correctly (12.2%). The difference between benefit and risk favored the first (Bayes Factor = 2.3).

Conclusions:

The benefit-risk balance for the use of the transfer factor (Hebertrans®) was in favor of the benefit, despite the fact that the clinical evolution of patients is not satisfactory, this drug causes few adverse reactions; the most frequent are related to the administration site and are mild. However, controlled epidemiological studies are necessary to verify these results.

Palavras-chave : transfer factor; adverse reactions; benefit-risk; pharmacoepidemiology.

        · resumo em Português | Espanhol | Francês     · texto em Espanhol     · Espanhol ( pdf )